Elanco Animal Health (NYSE:ELAN Shareholders Incur Further Losses as Stock Declines 6.8% This Week, Taking Three-year Losses to 58%
Elanco Animal Health (NYSE:ELAN Shareholders Incur Further Losses as Stock Declines 6.8% This Week, Taking Three-year Losses to 58%
The truth is that if you invest for long enough, you're going to end up with some losing stocks. But long term Elanco Animal Health Incorporated (NYSE:ELAN) shareholders have had a particularly rough ride in the last three year. Regrettably, they have had to cope with a 58% drop in the share price over that period. On top of that, the share price is down 6.8% in the last week.
事实是,如果你持有足够长的时间,最终会持有一些亏损股票。但从长期来看,纽交所上市企业elanco animal health(NYSE:ELAN)的股东在过去三年里经历了特别艰难的时期。遗憾的是,他们在那段时间内股价下跌了58%。除此之外,股价在上周下跌了6.8%。
Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.
考虑到过去一周对股东来说是艰难的,让我们调查一下基本面并看看我们能学到什么。
Given that Elanco Animal Health didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
考虑到elanco animal health过去十二个月没有盈利,我们将专注于营业收入增长,形成对其业务发展的快速观点。当一家公司没有盈利时,我们通常希望看到良好的营业收入增长。可以想象,快速的营业收入增长,如果保持,通常会导致快速的利润增长。
Over the last three years, Elanco Animal Health's revenue dropped 2.8% per year. That is not a good result. The share price decline of 16% compound, over three years, is understandable given the company doesn't have profits to boast of, and revenue is moving in the wrong direction. Having said that, if growth is coming in the future, now may be the low ebb for the company. We'd be pretty wary of this one until it makes a profit, because we don't specialize in finding turnaround situations.
在过去三年里,elanco animal health的营业收入每年下降了2.8%。这并不是一个好的结果。在过去三年里,股价下跌了16%,这是可以理解的,因为公司没有盈利可夸耀,而且营业收入走势不对。话虽如此,如果增长即将到来,现在可能是公司的低谷期。在它盈利之前,我们对它感到相当警惕,因为我们不擅长寻找扭转形势的情况。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以看到以下收益和营收的变化情况(通过单击图像了解精确值)。
It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. If you are thinking of buying or selling Elanco Animal Health stock, you should check out this free report showing analyst profit forecasts.
很高兴看到在过去三个月内有一些重要的内部人员买入。 这是一个积极的迹象。 话虽如此,我们认为收益和营业收入增长趋势更重要, 是否考虑购买或出售elanco animal health股票,您应该查看这份免费报告,其中包含分析师的利润预测。
A Different Perspective
不同的观点
Elanco Animal Health shareholders are up 23% for the year. Unfortunately this falls short of the market return. On the bright side, that's still a gain, and it is certainly better than the yearly loss of about 8% endured over half a decade. So this might be a sign the business has turned its fortunes around. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares - and the price they paid.
elanco animal health股东今年涨幅23%。 不幸的是,这低于市场回报。 值得一提的是,这仍然是一笔收益,肯定比半个世纪以来约8%的年度亏损好。 因此,这可能是业务已扭转命运的迹象。 如果您想进一步研究这支股票,内部人员买入数据是一个明显的开始地点。 您可以点击这里查看谁一直在买入股票-以及他们支付的价格。
Elanco Animal Health is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying.
Elanco Animal Health并不是唯一的股票内部人员在买入,因此,不妨看一下这份免费的小盘公司列表,这些公司的估值很有吸引力。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。